# Critic response

## Scope and disposition

This review is limited to the three findings in
`.ai_paper_validation/evidence_verifier_response_round1.md`. No new issues were
searched for or added. The verifier findings were checked against the cited
locations in the supplied article-package PDFs and the supporting checker
outputs.

| Candidate | Decision | Final severity | Critic rationale |
|---|---|---|---|
| 1. Table 5 total-cholesterol and LDL absolute differences | **Accepted, edited** | **Minor** | The displayed counts, denominators, group percentages, and `4.3` values are visible at the cited location, and the exact-count calculation reproducibly rounds to `4.4`. The two affected rows are one issue because they repeat identical inputs and the same discrepancy. The impact is confined to two point estimates. |
| 2. Placebo hospitalization percentage among relapses | **Accepted, edited** | **Minor** | The corrected location (D01 PDF page 8) and reported `11 (32.3%) of 34` are visible, and `11/34 × 100` reproducibly rounds to `32.4%`. The impact is a 0.1-percentage-point display error. |
| 3. HbA1c effect-estimate unit | **Accepted, materially narrowed** | **Minor** | The two main-text estimates are labeled `mg/dL`, while Table 4 and eFigure 8 label the same HbA1c outcome in `%`. This directly supports a presentation inconsistency. The verifier's stronger assertion that the number can remain unchanged after relabeling is not established by the supplied package; the final card therefore leaves the exact intended correction or any rescaling for human resolution. |

**Rejected findings:** None.

**Final retained issue count:** 3.

## Final evidence card 1

### Table 5 understates the absolute unadjusted difference by 0.1 percentage point in two rows

- **Issue statement:** In Table 5, both the total-cholesterol and LDL rows report an absolute unadjusted difference of `4.3%` for `9/64` versus `6/62`, although the exact percentage-point difference rounds to `4.4%` at the table's one-decimal precision.
- **Category:** Arithmetic inconsistency
- **Severity:** Minor
- **Exact location:** JAMA2019-10517-D01, `jama_flint_2019_oi_190079.pdf`, PDF page 9 (printed page 630), Table 5:
  - row `Cholesterol—Total (≥1 value above both participant's RCT baseline and 240 mg/dL)`;
  - row `LDL (≥1 value above both participant's RCT baseline and 160 mg/dL)`;
  - columns `Sertraline Plus, No. (%)—Olanzapine (n = 64)`, `Placebo (n = 62)`, and `Absolute Unadjusted Difference Between Groups, % (95% CI)`.
- **Reported values:**
  - Total cholesterol: olanzapine `9 (14.1)`, placebo `6 (9.7)`, reported difference `4.3 (−8 to 17.2)`.
  - LDL: olanzapine `9 (14.1)`, placebo `6 (9.7)`, reported difference `4.3 (−8 to 17.2)`.
- **Reported-versus-comparator comparison:** Reported difference in each row: `4.3%`. Difference calculated from the displayed counts and denominators: `4.385080645%`, which displays as `4.4%` to one decimal.
- **Reproducible calculation and tolerance:**
  - Formula: `100 × [(9/64) − (6/62)]`.
  - Inputs: `9` of `64` and `6` of `62`.
  - Result: `100 × (0.140625 − 0.0967741935) = 4.385080645` percentage points.
  - Component check: `100 × 9/64 = 14.0625% → 14.1%`; `100 × 6/62 = 9.677419% → 9.7%`.
  - Nearest-tenth tolerance: a displayed `4.4` represents `[4.35, 4.45)` percentage points; `4.385080645` falls within this interval. A displayed `4.3` represents `[4.25, 4.35)` and excludes the exact result.
- **Bounded impact:** The displayed point difference is understated by `0.1 percentage point` in two rows with identical inputs. The finding does not challenge the displayed event counts or denominators and makes no claim that the reported confidence intervals or the article's no-significant-group-difference statement change.

**Human verification steps**

1. Open JAMA2019-10517-D01, `jama_flint_2019_oi_190079.pdf`, PDF page 9 (printed page 630), Table 5.
2. Confirm that both cited rows show `9 (14.1)`, `6 (9.7)`, and `4.3 (−8 to 17.2)` under denominators `64` and `62`.
3. Calculate `100 × [(9/64) − (6/62)]`; a result of approximately `4.38508` percentage points confirms the exact-count comparator.
4. Round once to one decimal. `4.4`, rather than `4.3`, confirms the display inconsistency.
5. Resolve the issue only if the production output documents a different estimator or rounding convention for the displayed point difference that validly produces `4.3` from these reported inputs.

## Final evidence card 2

### The placebo hospitalization percentage among relapse participants is rounded incorrectly

- **Issue statement:** The article reports that `11 (32.3%) of 34` placebo-group participants who relapsed required psychiatric hospitalization, although `11/34` rounds to `32.4%` at one decimal.
- **Category:** Arithmetic inconsistency
- **Severity:** Minor
- **Exact location:** JAMA2019-10517-D01, `jama_flint_2019_oi_190079.pdf`, PDF page 8 (printed page 629), `Adverse Effects`, paragraph continuing at the top of the right column immediately before `Discussion`.
- **Reported excerpt:** `“6 (46.2%) of 13 in the olanzapine group and 11 (32.3%) of 34 in the placebo group”` required psychiatric hospitalization because of relapse.
- **Reported-versus-comparator comparison:** Reported placebo percentage: `32.3%`. Exact proportion from the numerator and denominator in the same sentence: `32.35294118%`, which displays as `32.4%` to one decimal. The adjacent olanzapine value supplies an internal comparator: `6/13 × 100 = 46.15384615% → 46.2%`, as reported.
- **Reproducible calculation and tolerance:**
  - Formula: `100 × 11/34`.
  - Inputs: `11` hospitalizations among `34` placebo-group relapse participants.
  - Result: `32.35294118%`.
  - Nearest-tenth tolerance: a displayed `32.4` represents `[32.35, 32.45)`; `32.35294118` lies inside that interval. A displayed `32.3` represents `[32.25, 32.35)` and excludes the exact proportion.
- **Bounded impact:** The placebo percentage is understated by `0.1 percentage point`. The reported numerator, denominator, hospitalization count, and substantive statement that these relapse participants required hospitalization are unchanged.

**Human verification steps**

1. Open JAMA2019-10517-D01, `jama_flint_2019_oi_190079.pdf`, PDF page 8 (printed page 629), top of the right column immediately before `Discussion`.
2. Confirm the sentence reports `11 (32.3%) of 34` for placebo and `6 (46.2%) of 13` for olanzapine.
3. Calculate `100 × 11/34`; approximately `32.35294%` confirms the exact placebo proportion.
4. Round once to one decimal. `32.4%`, rather than `32.3%`, confirms the inconsistency.
5. Confirm that `100 × 6/13 = 46.15385% → 46.2%`; this adjacent value corroborates nearest-tenth rounding. A documented alternate convention would be needed to resolve the issue otherwise.

## Final evidence card 3

### The HbA1c treatment-by-time estimate is assigned conflicting units

- **Issue statement:** The abstract and Results label the HbA1c treatment-by-linear-time estimate and confidence interval in `mg/dL`, while Table 4 and eFigure 8 label the same HbA1c outcome in `%`.
- **Category:** Presentation inconsistency
- **Severity:** Minor
- **Reported-unit locations and excerpts:**
  1. JAMA2019-10517-D01, `jama_flint_2019_oi_190079.pdf`, PDF page 1 (printed page 622), abstract, `RESULTS`: `“HbA1c levels (−0.0002 mg/dL; 95% CI, −0.0021 to 0.0016)”`.
  2. JAMA2019-10517-D01, same filename, PDF page 7 (printed page 628), `Secondary Outcomes`, right column: `“HbA1c levels (−0.0002 mg/dL [95% CI, −0.0021 to 0.0016], adjusted P = .99)”`. The paragraph identifies the reported quantity as the effect on the `daily rate` and the `treatment × linear time interaction`.
- **Comparator-unit locations and values:**
  1. JAMA2019-10517-D01, same filename, PDF page 8 (printed page 629), Table 4, row `HbA1c, %`: olanzapine baseline `5.9 (1.5)` and termination `5.7 (1.1)`; placebo baseline `5.9 (1.2)` and termination `5.9 (1.0)`.
  2. JAMA2019-10517-D03, `joi190079supp2_prod.pdf`, PDF page 9, `eFigure8. Mixed Model Estimated Least Square Means of HbA1c in Randomized Groups in the STOP-PD II Clinical Trial`: y-axis `HbA1c (%)`; x-axis `Day`.
- **Reported-versus-comparator comparison:** Main-text coefficient and CI unit: `mg/dL`. Same named outcome in the main table and corresponding mixed-model figure: `%`. The supplied package states no conversion reconciling these dimensions.
- **Reproducible logical chain and tolerance:**
  1. The Results define `−0.0002` as the treatment-by-linear-time effect on the daily rate of HbA1c.
  2. Table 4 explicitly labels HbA1c in `%`.
  3. The corresponding mixed-model eFigure 8 plots `HbA1c (%)` against `Day`.
  4. A model rate coefficient inherits the modeled outcome dimension per its time dimension unless a conversion is stated. Thus a percent-scale HbA1c trajectory supports a percent-scale rate, while `mg/dL` is incompatible with the displayed outcome scale.
  5. Rounding tolerance is not applicable to a categorical unit conflict.
- **Bounded impact:** The inconsistency affects the interpretation of one secondary-outcome estimate and CI repeated in two main-text locations. It does not establish that the numerical estimate, CI, adjusted `P = .99`, or no-difference conclusion is wrong. The supplied package does not determine whether the intended correction is label-only or requires numerical rescaling.

**Human verification steps**

1. Open D01 PDF page 1, abstract `RESULTS`, and confirm that `−0.0002` and its CI are labeled `mg/dL`.
2. Open D01 PDF page 7, `Secondary Outcomes`, and confirm the repeated estimate/CI, `mg/dL` label, and description of a daily-rate treatment-by-linear-time effect.
3. Open D01 PDF page 8, Table 4, and confirm the row label `HbA1c, %` and the cited values.
4. Open D03 PDF page 9, eFigure 8, and confirm the y-axis `HbA1c (%)` and x-axis `Day`.
5. Confirm that all locations refer to the same HbA1c outcome. The conflicting displayed dimensions confirm the presentation inconsistency.
6. To resolve the exact correction, inspect the model-output variable definition or an authoritative publisher correction. Documentation of a conversion may establish a rescaled value; confirmation that the outcome was modeled directly in percent units would establish the appropriate percent-scale rate label.
